Compare TMCI & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | CRBP |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.6M | 170.3M |
| IPO Year | 2021 | N/A |
| Metric | TMCI | CRBP |
|---|---|---|
| Price | $2.59 | $8.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $6.87 | ★ $50.29 |
| AVG Volume (30 Days) | ★ 777.8K | 509.7K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $218,879,000.00 | N/A |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $1.07 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.90 | N/A |
| 52 Week Low | $2.44 | $4.64 |
| 52 Week High | $10.79 | $20.56 |
| Indicator | TMCI | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 29.93 | 24.29 |
| Support Level | $2.64 | $9.44 |
| Resistance Level | $2.76 | $11.64 |
| Average True Range (ATR) | 0.20 | 0.71 |
| MACD | 0.09 | -0.16 |
| Stochastic Oscillator | 27.17 | 0.27 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.